DES    Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound Am Heart J, 2010. 159(2): p. 271-7. T. Kubo, et al., Does "late catch-up" exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents Am Heart J, 2010. 159(3): p. 446-453 e3. K. W. Park, et al., Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet, 2010. K. Rasmussen, et al., Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial EuroIntervention, 2010. 5(6): p. 692-7. I. T. Meredith, et al., The Paclitaxel-Eluting Coroflex Stent Study II (PECOPS II) Acute and 6-Month Clinical and Angiographic Follow-Up, 1-Year Clinical Follow-Up J Interv Cardiol, 2010. M. Wiemer, et al., Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry Circ Cardiovasc Interv, 2010. 3(1): p. 42-9. W. M. Wolf, et al., Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet, 2010. 375(9710): p. 201-9. E. Kedhi, et al., Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease Circ J, 2010. 74(3): p. 442-8. S. S. Kim, et al., Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET Eur Heart J, 2009. 30(1): p. 16-24. M. Pfisterer, et al., Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events Eur Heart J, 2009. 30(3): p. 321-9. P. G. Steg, et al., Distribution of angiographic measures of restenosis after drug-eluting stent implantation Heart, 2009. 95(19): p. 1572-8. R. A. Byrne, et al., Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results Heart, 2009. 95(18): p. 1489-94. R. A. Byrne, et al., Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry Heart, 2009. 95(19): p. 1579-86. K. J. Harjai, et al., Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents Heart, 2009. 95(12): p. 970-5. W. C. Kang, et al., Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents Heart, 2009. 95(23): p. 1907-12. J. S. Kim, et al., Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II) Heart, 2009. 95(13): p. 1061-6. N. Kukreja, et al., Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents Heart, 2009. 95(19): p. 1587-92. Z. J. Wang, et al., Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings J Am Coll Cardiol, 2009. 53(22): p. 2053-60. F. Alfonso, et al., A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial J Am Coll Cardiol, 2009. 53(11): p. 919-28. E. S. Brilakis, et al., 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents J Am Coll Cardiol, 2009. 54(10): p. 894-902. A. Caixeta, et al., Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria J Am Coll Cardiol, 2009. 53(16): p. 1389-98. J. Carlsson, et al., Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry J Am Coll Cardiol, 2009. 53(18): p. 1629-41. P. S. Douglas, et al., Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry) J Am Coll Cardiol, 2009. 53(18): p. 1660-7. O. Frobert, et al., 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry) J Am Coll Cardiol, 2009. 53(8): p. 658-64. A. Kaltoft, et al., A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction J Am Coll Cardiol, 2009. 53(18): p. 1653-9. J. W. Kim, et al., Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications J Am Coll Cardiol, 2009. 53(19): p. 1773-82. D. T. Ko, et al., Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry J Am Coll Cardiol, 2009. 54(9): p. 853-9. J. Y. Lee, et al., Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease J Am Coll Cardiol, 2009. 53(19): p. 1760-8. J. Mehilli, et al., The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry J Am Coll Cardiol, 2009. 54(3): p. 269-76. Y. Onuma, et al., Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation J Am Coll Cardiol, 2009. 53(24): p. 2298-305. H. Ota, et al., Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study) J Am Coll Cardiol, 2009. 54(13): p. 1131-6. I. Sheiban, et al., Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol, 2009. 53(10): p. 849-56. D. Sibbing, et al., Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis J Am Coll Cardiol, 2009. 53(25): p. 2324-31. H. Thiele, et al., Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry J Am Coll Cardiol, 2009. 53(16): p. 1399-409. J. W. van Werkum, et al., 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study J Am Coll Cardiol, 2009. 53(12): p. 1031-9. S. Verheye, et al., Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial J Am Coll Cardiol, 2009. 53(17): p. 1488-97. G. Weisz, et al., A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet, 2009. 373(9667): p. 897-910. P. W. Serruys, et al., Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden N Engl J Med, 2009. 360(19): p. 1933-45. S. K. James, et al., CABG vs. stenting--clinical implications of the SYNTAX trial N Engl J Med, 2009. 360(8): p. e10. T. H. Lee, L. D. Hillis and E. G. Nabel, Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med, 2009. 360(10): p. 961-72. P. W. Serruys, et al., Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction N Engl J Med, 2009. 360(19): p. 1946-59. G. W. Stone, et al., Fractional flow reserve versus angiography for guiding percutaneous coronary intervention N Engl J Med, 2009. 360(3): p. 213-24. P. A. Tonino, et al., Drug-eluting stents: a study of international practice Am Heart J, 2009. 158(4): p. 576-84. D. Austin, et al., The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents Am Heart J, 2009. 157(5): p. 899-907. M. J. Butler, et al., Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial Am Heart J, 2009. 158(4): p. e43-50. E. Di Lorenzo, et al., Optical coherence tomography patterns of stent restenosis Am Heart J, 2009. 158(2): p. 284-93. N. Gonzalo, et al., Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice Am Heart J, 2009. 157(5): p. 883-8. J. J. Goy, et al., Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial Am Heart J, 2009. 158(6): p. 1005-10. J. B. Hermiller, et al., Patterns of use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents Am Heart J, 2009. 158(4): p. 592-598 e1. D. T. Ko, et al., Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents Am Heart J, 2009. 158(2): p. 271-6. G. Leibundgut, et al., High-intensity interval training may reduce in-stent restenosis following percutaneous coronary intervention with stent implantation A randomized controlled trial evaluating the relationship to endothelial function and inflammation Am Heart J, 2009. 158(5): p. 734-41. P. S. Munk, et al., Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation Am Heart J, 2009. 158(1): p. 92-8. T. Ota, et al., Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study) Am Heart J, 2009. 157(1): p. 149-55. B. M. Rahel, et al., Drug-eluting versus bare-metal stents for treating saphenous vein grafts Am Heart J, 2009. 158(4): p. 637-43. M. H. Shishehbor, et al., Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study Am Heart J, 2009. 157(5): p. 908-12. J. W. Suh, et al., Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy Am Heart J, 2009. 158(1): p. 99-104. M. Yamamoto, et al., Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries Am J Cardiol, 2009. 103(4): p. 496-500. L. Bonello, et al., Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial Am J Cardiol, 2009. 104(2): p. 210-5. M. Busk, et al., Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture Am J Cardiol, 2009. 103(6): p. 818-23. H. Doi, et al., Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes Am J Cardiol, 2009. 104(9): p. 1210-5. D. N. Feldman, et al., Racial disparities in outcomes following percutaneous coronary intervention with drug-eluting stents Am J Cardiol, 2009. 103(5): p. 653-8. M. A. Gaglia, Jr., et al., Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]) Am J Cardiol, 2009. 104(3): p. 338-42. M. Gilard, et al., Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol, 2009. 103(6): p. 806-11. B. Giusti, et al., Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease Am J Cardiol, 2009. 103(2): p. 194-8. Y. Han, et al., Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings Am J Cardiol, 2009. 103(11): p. 1537-45. K. J. Harjai, et al., Serial intravascular ultrasound analysis of peri-stent remodeling and proximal and distal edge effects after sirolimus-eluting or paclitaxel-eluting stent implantation in patients with diabetes mellitus Am J Cardiol, 2009. 103(8): p. 1083-8. L. O. Jensen, et al., Paclitaxel-eluting stent long-term outcomes in percutaneous saphenous vein graft interventions (PELOPS) study Am J Cardiol, 2009. 103(2): p. 199-202. M. H. Jim, et al., Impact of different re-stenting strategies on expansion of a drug-eluting stent implanted to treat bare-metal stent restenosis Am J Cardiol, 2009. 104(4): p. 531-7. L. Kalinczuk, et al., Comparison of long versus short ("spot") drug-eluting stenting for long coronary stenoses Am J Cardiol, 2009. 104(6): p. 786-90. D. G. Katritsis, et al., Three-year survival following multivessel percutaneous coronary intervention with bare-metal or drug-eluting stents in unselected patients Am J Cardiol, 2009. 103(2): p. 203-11. N. Kukreja, et al., Optical coherence tomographic results at six-month follow-up evaluation of the CATANIA coronary stent system with nanothin Polyzene-F surface modification (from the Assessment of The LAtest Non-Thrombogenic Angioplasty Stent [ATLANTA] trial) Am J Cardiol, 2009. 103(11): p. 1551-5. A. La Manna, et al., Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program Am J Cardiol, 2009. 103(12): p. 1663-71. J. M. Lasala, et al., Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction Am J Cardiol, 2009. 104(10): p. 1370-6. C. W. Lee, et al., Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation Am J Cardiol, 2009. 104(1): p. 41-5. G. Lemesle, et al., An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents Am J Cardiol, 2009. 103(4): p. 501-6. J. Liu, et al., Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial Am J Cardiol, 2009. 103(3): p. 345-9. M. Maeng, et al., One-year outcomes from the TAXUS express stent versus cypher stent Am J Cardiol, 2009. 103(7): p. 930-6. M. Mayor, et al., Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry) Am J Cardiol, 2009. 104(10): p. 1362-9. C. A. Nienaber, et al., Relation of drug-eluting stent strut distribution to stent thrombosis in coronary arteries Am J Cardiol, 2009. 104(3): p. 343-8. M. P. Opolski, et al., Association of a unique cardiovascular risk profile with outcomes in Hispanic patients referred for percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry) Am J Cardiol, 2009. 104(6): p. 775-9. S. V. Parikh, et al., Prognostic influence of diabetes mellitus on long-term clinical outcomes and stent thrombosis after drug-eluting stent implantation in asian patients Am J Cardiol, 2009. 103(5): p. 646-52. D. W. Park, et al., Effectiveness of primary percutaneous coronary interventions for stent thrombosis Am J Cardiol, 2009. 103(7): p. 913-6. G. Parodi, et al., Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study) Am J Cardiol, 2009. 103(2): p. 181-6. M. R. Patel, et al., Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction Am J Cardiol, 2009. 103(12): p. 1672-4. B. Pierre-Louis, et al., Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis Am J Cardiol, 2009. 104(4): p. 525-30. T. L. Pinto Slottow, et al., A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation Am J Cardiol, 2009. 103(7): p. 923-9. J. J. Popma, et al., Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention Am J Cardiol, 2009. 103(10): p. 1339-43. M. J. Price, et al., Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation Am J Cardiol, 2009. 103(6): p. 801-5. P. Roy, et al., Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents Am J Cardiol, 2009. 103(4): p. 491-5. D. H. Steinberg, et al., Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes Am J Cardiol, 2009. 103(2): p. 187-93. C. Tamburino, et al., Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study) Am J Cardiol, 2009. 104(10): p. 1357-61. G. Tanzilli, et al., Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents Am J Cardiol, 2009. 104(9): p. 1229-34. J. P. van Kuijk, et al., Comparison of neointimal hyperplasia with drug-eluting stents versus bare metal stents in patients undergoing intracoronary bone-marrow mononuclear cell transplantation following acute myocardial infarction Am J Cardiol, 2009. 103(12): p. 1651-6. A. Villa, et al., Outcome of patients treated by a novel thin-strut cobalt-chromium stent in the drug-eluting stent era: Results of the SKICE (Skylor in real world practice) registry Catheter Cardiovasc Interv, 2009. 73(4): p. 457-65. F. Burzotta, et al., Long-term clinical benefit of drug-eluting stents over bare-metal stents in diabetic patients with de novo left main coronary artery disease: results from a real-world multicenter registry Catheter Cardiovasc Interv, 2009. 73(3): p. 310-6. D. Capodanno, et al., Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial Catheter Cardiovasc Interv, 2009. 73(6): p. 771-9. V. Dzavik, et al., Outcomes after percutaneous coronary intervention of ostial lesions in the era of drug-eluting stents Catheter Cardiovasc Interv, 2009. 73(6): p. 763-8. M. Freeman, et al., Defining a new standard for IVUS optimized drug eluting stent implantation: the PRAVIO study Catheter Cardiovasc Interv, 2009. 74(2): p. 348-56. R. T. Gerber, et al., Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial Catheter Cardiovasc Interv, 2009. 73(1): p. 34-41. T. Hasegawa, et al., Impact of a prolonged delivery inflation time for optimal drug-eluting stent expansion Catheter Cardiovasc Interv, 2009. 73(2): p. 205-11. T. Kawasaki, et al., The incidence and predictors of postprocedural incomplete stent apposition after angiographically successful drug-eluting stent implantation Catheter Cardiovasc Interv, 2009. 74(1): p. 58-63. Y. S. Kim, et al., Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial Catheter Cardiovasc Interv, 2009. 74(5): p. 719-27. A. J. Lansky, et al., Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction Catheter Cardiovasc Interv, 2009. 73(1): p. 15-21. M. S. Lee, et al., Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial Catheter Cardiovasc Interv, 2009. 74(5): p. 665-73. P. A. Lemos, et al., Comparing long-term outcomes between drug-eluting and bare-metal stents in the treatment of cardiac allograft vasculopathy Catheter Cardiovasc Interv, 2009. 74(4): p. 543-9. T. Nfor, et al., Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry Catheter Cardiovasc Interv, 2009. 73(7): p. 874-80. V. Novack, et al., A comparison of the mechanical performance characteristics of seven drug-eluting stent systems Catheter Cardiovasc Interv, 2009. 73(3): p. 350-60. W. Schmidt, et al., Early and long-term results of percutaneous coronary intervention for unprotected left main trifurcation disease Catheter Cardiovasc Interv, 2009. 73(1): p. 25-31. I. Sheiban, et al., Very long-term results comparing a simple versus a complex stenting strategy in the treatment of coronary bifurcation lesions Catheter Cardiovasc Interv, 2009. 74(2): p. 313-20. I. Sheiban, et al., Strategies for drug-eluting stent treatment of bifurcation coronary artery disease in the United States: insights from the e-Cypher S.T.L.L.R.trial Catheter Cardiovasc Interv, 2009. 73(7): p. 890-7. N. Suzuki, et al., Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease Catheter Cardiovasc Interv, 2009. 73(3): p. 291-8. C. Tamburino, et al., Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry Catheter Cardiovasc Interv, 2009. 73(2): p. 243-8. C. Tamburino, et al., PCI versus CABG for multivessel coronary disease in diabetics Catheter Cardiovasc Interv, 2009. 73(1): p. 50-8. G. Tarantini, et al., The paclitaxel-eluting Coroflex Please stent study (PECOPS I): the 3-year clinical follow-up Catheter Cardiovasc Interv, 2009. 74(5): p. 674-82. M. Unverdorben, et al., Long-term clinical and angiographic outcomes after implantation of sirolimus-eluting stents with a "modified mini-crush" technique in coronary bifurcation lesions Catheter Cardiovasc Interv, 2009. 74(1): p. 76-84. H. M. Yang, et al., Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial Circulation, 2009. 119(5): p. 687-98. J. Aoki, et al., Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention Circulation, 2009. 119(25): p. 3207-14. K. Y. Chen, et al., Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study Circulation, 2009. 119(1): p. 71-8. A. Colombo, et al., Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis Circulation, 2009. 120(5): p. 391-9. S. Cook, et al., Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial Circulation, 2009. 120(11): p. 964-72. E. Di Lorenzo, et al., Sirolimus-eluting stent treatment at high-volume centers confers lower mortality at 6-month follow-up: results from the prospective multicenter German Cypher Registry Circulation, 2009. 120(7): p. 600-6. A. A. Khattab, et al., Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents Circulation, 2009. 120(5): p. 400-7. Y. H. Kim, et al., Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation Circulation, 2009. 119(7): p. 987-95. T. Kimura, et al., Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation, 2009. 119(25): p. 3198-206. A. J. Kirtane, et al., Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution Circulation, 2009. 119(15): p. 2040-50. Y. Li, et al., Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy Circulation, 2009. 120(19): p. 1875-82. A. Maehara, et al., Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation, 2009. 119(2): p. 237-42. R. Marcucci, et al., High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease Circulation, 2009. 120(22): p. 2214-21. A. Migliorini, et al., C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation Circulation, 2009. 120(20): p. 1987-95. D. W. Park, et al., Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial Circulation, 2009. 120(20): p. 1978-86. J. Rodes-Cabau, et al., Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program Circulation, 2009. 119(7): p. 952-61. J. Ryan, et al., Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions Circulation, 2009. 120(15): p. 1498-504. S. Silber, et al., Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial Circulation, 2009. 119(5): p. 680-6. G. W. Stone, et al., Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry Circulation, 2009. 120(19): p. 1866-74. M. Toyofuku, et al., Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis Circulation, 2009. 119(23): p. 2986-94. M. Unverdorben, et al., Unprotected left main stenting in the real world: two-year outcomes of the French left main taxus registry Circulation, 2009. 119(17): p. 2349-56. B. Vaquerizo, et al., A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents Eur Heart J, 2009. 30(8): p. 923-31. R. A. Byrne, et al., ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007 Eur Heart J, 2009. 30(2): p. 152-61. J. Daemen, et al., Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety? Eur Heart J, 2009. 30(15): p. 1828-30. A. V. Finn, et al., Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents Eur Heart J, 2009. 30(11): p. 1340-7. G. Niccoli, et al., MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses Eur Heart J, 2009. 30(12): p. 1477-85. Y. Onuma, et al.,